Doreen Chan
Associate Director, Clinical Research Akero Therapeutics
Seminars
Thursday 17th September 2026
Demonstrating Fibrosis Regression Through Non-Invasive Assessments in the Ph2b SYMMETRY Trial of Efruxifermin: Advancing Development in Compensated Cirrhosis Due to MASH
11:30 am
- Evaluating changes in multiple non-invasive tests to assess fibrosis regression and disease improvement, enabling more comprehensive treatment monitoring and supporting development in advanced MASH populations
- Leveraging longitudinal non-invasive assessment approaches to characterize therapeutic impact over time, improving understanding of disease modification and strengthening clinical decision-making
- Generating evidence of improvement across measures associated with advanced liver disease to support development strategies, enabling greater confidence in therapeutic benefit and improving future patient outcomes
Thursday 17th September 2026
Panel Discussion: Defining The Future Mash Treatment Landscape To Prioritize Differentiated Therapies, Optimize Combination Strategies & Establish Long-Term Standards Of Care
3:30 pm
- Defining future standards of care across fibrosis, metabolic dysfunction and advanced disease populations to prioritize differentiated therapies, improving long-term clinical and commercial positioning
- Evaluating how combination strategies and emerging mechanisms will shape the post-Rezdiffra treatment landscape to optimize development planning, enabling stronger therapeutic differentiation and improved patient outcomes
- Identifying the clinical, regulatory and competitive factors that will determine best-in-class therapies to strengthen late-stage development strategies, improving adoption potential and long-term market success
